One clinical study showed that in patients with platinum-resistant BRCA1/2 mutation ovarian cancer, olaparib as maintenance monotherapy showed a progression-free survival (PFS) of 11.2 months compared to 4.3 months with placebo, a dramatic improvement for treating ovarian cancer patients 17. This evidence concerns the gene BRCA1 and ovarian cancer.